Research Paper Volume 12, Issue 15 pp 15374—15391

Figure 5. Oncogenic activity of SCD1 in xenograft mice model. (A) Representative mice and tumor nodules in each group were shown. (B) Tumor volumes were analyzed (n = 5), results were shown as mean ± SEM (Student t test). (C) Tumor weights were calculated (n = 5), results were shown as mean ± SEM (Student t test). (D) Immunofluorescent staining of the indicated markers were performed. Scale bar, 50 μm. (E) the SCD1, Twist1 and Ki67 positive cells in the tumors were analyzed by using image J software, and results were shown as mean ± SEM (Student t test). (F) Representative mice and tumor nodules in each group were shown. (G) tumor volumes were analyzed (n = 3), results were shown as mean ± SEM (the analysis of variance test). (H) Tumor weights were calculated (n = 3), and results were shown as mean ± SEM (the analysis of variance test). (I) Mice were treated by SCD1 inhibitor A939572 or Vehicle i.p. All regimens were administered for twice a week. Body weight was measured weekly during the treatment. There was no obvious decrease in body weight when administration of A939572. *, P <0.05; **, P <0.01; ***, P <0.001; ****, P <0.0001; NS, no significance, respectively.